TWi Biotechnology, Inc. (TPEX:6610)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
19.40
+0.05 (0.26%)
Mar 24, 2026, 1:46 PM CST
Market Cap2.11B +82.4%
Revenue (ttm)n/a
Net Income-155.28M
EPS-1.77
Shares Out107.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume234,179
Average Volume246,237
Open20.00
Previous Close19.35
Day's Range19.00 - 20.00
52-Week Range8.96 - 40.85
Beta0.63
RSI41.14
Earnings DateApr 2, 2026

About TWi Biotechnology

TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseas... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 23
Stock Exchange Taipei Exchange
Ticker Symbol 6610
Full Company Profile

Financial Performance

Financial Statements